DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.
about
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumorsIdentification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancerIntegrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients.Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression dataIroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cellsAn early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysisA novel method for identification and quantification of consistently differentially methylated regionsEpigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesisAlu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.Cancer module genes ranking using kernelized score functionsMicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survivalGenomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancersA quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.Insight into the heterogeneity of breast cancer through next-generation sequencing.Breast cancer - one term, many entities?Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer StudyGene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.Epigenetic regulation of mucin genes in human cancersThe effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signaturesBTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapySubtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines.Kruppel-like factor 4 signals through microRNA-206 to promote tumor initiation and cell survival.DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.Luminal B breast cancer subtype displays a dicotomic epigenetic patternDecreased expression of BTG3 was linked to carcinogenesis, aggressiveness, and prognosis of ovarian carcinoma.Identification of Genetic and Epigenetic Variants Associated with Breast Cancer Prognosis by Integrative Bioinformatics Analysis.Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry.DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer.NKL homeobox genes in leukemia.DNA methylome profiling beyond promoters - taking an epigenetic snapshot of the breast tumor microenvironment.Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in CancerKruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses.The CpG island methylator phenotype in breast cancer is associated with the lobular subtype.
P2860
Q28302352-9A2299B0-2403-472E-A352-54CDCA048C86Q28741689-99107BA1-6A85-4677-A9FC-F053AA836D52Q30910707-EE173179-6647-4D01-B38F-CC76154A141EQ31031642-69EF9604-0F97-48FC-9F1E-C50D53CE9189Q31814868-036498CB-33B3-42DB-9FCD-F390549DE7BBQ33591859-B8022748-4BDA-4AA3-B906-B7927CD46358Q33599244-A9F83866-42C7-4B96-B943-5A87E4627D01Q33739319-DE8BAC13-306E-4264-839A-FCD59F727021Q33817330-C7584C60-37D0-4EA7-ABD6-980BF179F00EQ33893710-D1204B9E-1332-44CA-A3AB-557063E5E49BQ34196315-43350643-B53D-4223-9FCE-8CC87EFD6ECAQ34456928-91C714BD-E33B-4039-BE7A-B26B96047739Q34592684-4092875A-7A65-417C-8CA2-AA1C1AAD1FE7Q35000317-25335181-3484-417F-AAF1-5D9E2DE4774AQ35002412-7BA67A56-BCA9-479D-A34C-4D90B5E142DCQ35031170-01922B89-AF50-4840-BCFF-ADF301B3BD84Q35274741-FBFA720A-04FE-4C87-8163-D946D6293CBAQ35370090-AE5C0612-2D87-42E5-9719-0667754294B7Q35370118-C1931BA4-1D85-46B1-9CC1-1A728042BB97Q35674941-36FEA315-B43B-4B80-9D1F-69CECE9936B5Q35802220-93F7DCF6-1789-4F0A-813A-EF97BC6B0A28Q35841605-358D5953-1D49-4DD2-83EE-E978E04373F1Q36001870-E1A20F38-AAAE-4A8D-9269-6E4A072933D7Q36089048-741093AB-2005-4F06-B848-285EDEBFECE2Q36260620-F6EC9BFF-475C-4848-81F3-A4F3E39163A7Q36268784-F5E40CB9-6C9F-4608-A785-CFF49AE189E5Q36579803-237AD66C-FA6D-4624-9479-6CB311D33807Q36833424-B6CC2B31-BB0A-4810-8202-E90DD2D71FDAQ36910353-370B50AD-C19A-4AB0-BA8A-029BA8876796Q37203783-8CCAD80A-E565-4F9E-B4F4-54FD57658E35Q37577093-6363340A-7792-47B2-89B4-09B00EBDF88FQ37649665-C5B5D193-ADF5-42AF-8017-AADEC7A5B481Q37702047-471D4A02-F9DD-4988-987D-AC6743389E07Q37706066-011CC902-C5D7-4B96-A483-5A1AD8576D68Q37957618-548A399C-5CEF-4FA1-BDC8-D66AB42A0AC7Q38261602-7AEC144E-98C6-41FF-A44F-F2418E707E48Q38547141-3AEB8EE9-5828-4D9D-A231-93B1C868338FQ38548766-F3238990-3464-48C5-8282-5BE03C34584BQ38768833-4796E6A6-063B-4177-A88B-D1D3BAB45E6FQ38944944-6E902A9D-B425-479F-812F-77DCBBF1F7CD
P2860
DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
DNA methylation patterns in lu ...... t of other clinical variables.
@en
type
label
DNA methylation patterns in lu ...... t of other clinical variables.
@en
prefLabel
DNA methylation patterns in lu ...... t of other clinical variables.
@en
P2093
P2860
P50
P1433
P1476
DNA methylation patterns in lu ...... t of other clinical variables.
@en
P2093
Ellen Schlichting
Harish Rotti
Hege E Giercksky Russnes
James B Hicks
Jude Kendall
K Satyamoorthy
K Shama Prasada
Marit Synnestvedt
P2860
P356
10.1016/J.MOLONC.2010.11.002
P577
2010-12-02T00:00:00Z